Logo image of 9VC.DE

ATAI BECKLEY NV (9VC.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:9VC - NL0015000DX5 - Common Stock

3.827 EUR
-0.01 (-0.18%)
Last: 12/9/2025, 7:00:00 PM

9VC.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap1.39B
Revenue(TTM)308.00K
Net Income(TTM)-149.27M
Shares363.19M
Float348.33M
52 Week High6
52 Week Low1.06
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.7
PEN/A
Fwd PEN/A
Earnings (Next)03-16 2026-03-16/amc
IPO2021-06-18
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


9VC.DE short term performance overview.The bars show the price performance of 9VC.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

9VC.DE long term performance overview.The bars show the price performance of 9VC.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of 9VC.DE is 3.827 EUR. In the past month the price increased by 2.05%. In the past year, price increased by 165.49%.

ATAI BECKLEY NV / 9VC Daily stock chart

9VC.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
SNW.DE SANOFI 10.95 202.21B
1SAN.MI SANOFI 10.95 202.21B
SAN.PA SANOFI 10.88 200.83B
MRK.DE MERCK KGAA 13.63 50.56B
UCB.BR UCB SA 37.73 47.11B
UNC.DE UCB SA 37.68 47.05B
BAYN.DE BAYER AG-REG 6.86 35.97B
1BAYN.MI BAYER AG-REG 6.8 35.65B
IPN.PA IPSEN 11.83 10.18B
REC.MI RECORDATI INDUSTRIA CHIMICA 23.99 9.88B
TUB.BR FINANCIERE DE TUBIZE 103.85 9.61B
VIRP.PA VIRBAC SA 19.61 2.85B

About 9VC.DE

Company Profile

9VC logo image ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.

Company Info

ATAI BECKLEY NV

Prof. J.H.Bavincklaan 7

Amstelveen NOORD-HOLLAND NL

Employees: 54

9VC Company Website

9VC Investor Relations

Phone: 31207932536

ATAI BECKLEY NV / 9VC.DE FAQ

What does ATAI BECKLEY NV do?

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. The company is headquartered in Amstelveen, Noord-Holland and currently employs 54 full-time employees. The company went IPO on 2021-06-18. The firm focused on developing treatments for mental health disorders. The firm's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.


What is the stock price of ATAI BECKLEY NV today?

The current stock price of 9VC.DE is 3.827 EUR. The price decreased by -0.18% in the last trading session.


Does 9VC stock pay dividends?

9VC.DE does not pay a dividend.


What is the ChartMill rating of ATAI BECKLEY NV stock?

9VC.DE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Would investing in ATAI BECKLEY NV be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 9VC.DE.


Is ATAI BECKLEY NV (9VC.DE) expected to grow?

The Revenue of ATAI BECKLEY NV (9VC.DE) is expected to grow by 468.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the next earnings date for 9VC stock?

ATAI BECKLEY NV (9VC.DE) will report earnings on 2026-03-16, after the market close.


9VC.DE Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to 9VC.DE. When comparing the yearly performance of all stocks, 9VC.DE is one of the better performing stocks in the market, outperforming 98.14% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

9VC.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to 9VC.DE. While 9VC.DE has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

9VC.DE Financial Highlights

Over the last trailing twelve months 9VC.DE reported a non-GAAP Earnings per Share(EPS) of -0.7.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.24%
ROE -93.44%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-75%
Sales Q2Q%1772.5%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)-1.91%

9VC.DE Forecast & Estimates

17 analysts have analysed 9VC.DE and the average price target is 10.57 EUR. This implies a price increase of 176.08% is expected in the next year compared to the current price of 3.827.

For the next year, analysts expect an EPS growth of 30.67% and a revenue growth 468.61% for 9VC.DE


Analysts
Analysts83.53
Price Target10.57 (176.2%)
EPS Next Y30.67%
Revenue Next Year468.61%

9VC.DE Ownership

Ownership
Inst Owners12.05%
Ins Owners3.7%
Short Float %N/A
Short RatioN/A